UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)

Annals of oncology, 2015-04, Vol.26 (4), p.709-714

2015

Volltextzugriff (PDF)

ES09.03 How I Decide 1st Line Treatment Options for Metastatic NSCLC Without Driver Mutations - Balancing Efficacy, Toxicity and Cost

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S36-S36

Frueh, M.

2019

Volltextzugriff (PDF)

Prognostic impact of the use of antibiotics in patients with advanced non-small cell lung cancer (NSCLC) receiving PD-(L)1 targeting monoclonal antibodies

Annals of oncology, 2019-04, Vol.30, p.ii58-ii58

2019

Volltextzugriff (PDF)

SAKK 17/16 - Lurbinectedin monotherapy in patients with progressive malignant pleural mesothelioma: A multicenter, single-arm phase II trial

Annals of oncology, 2018-10, Vol.29, p.viii644-viii644

2018

Volltextzugriff (PDF)

Treatment (tx) characteristics of patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) receiving atezolizumab (atezo) monotherapy in US clinical practice

Annals of oncology, 2019-04, Vol.30, p.ii65-ii65

2019

Volltextzugriff (PDF)

61PD 24h-blood profile gene expression biomarkers of the response to targeted therapy in advanced non-squamous non-small cell lung cancer (NSCLC)

Journal of thoracic oncology, 2016-04, Vol.11 (4), p.S81-S81

2016

Volltextzugriff (PDF)

IMpower150: Clinical safety, tolerability and immune-related adverse events in a phase III study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous NSCLC

Annals of oncology, 2018-10, Vol.29, p.viii498-viii499

2018

Volltextzugriff (PDF)

A multiwavelength study of the M dwarf binary YY Geminorum

Monthly notices of the Royal Astronomical Society, 2015-02, Vol.446 (4), p.4205-4205

2015

Volltextzugriff (PDF)

169P Chemotherapy is not superior to erlotinib in pretreated patients with advanced non-small cell lung cancer (NSCLC): A retrospective study

Journal of thoracic oncology, 2016-04, Vol.11 (4), p.S131-S131

2016

Volltextzugriff (PDF)

143PD Bevacizumab and pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous NSCLC: Results of the expanded SAKK19/09 trial

Journal of thoracic oncology, 2016-04, Vol.11 (4), p.S120-S120

2016

Volltextzugriff (PDF)

One-step, wash-free, bead-based immunoassay employing bound-free phase detection

Analytica chimica acta, 2021-04, Vol.1153, p.338280-338280, Article 338280

2021

Volltextzugriff (PDF)

Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2013-10, Vol.24 Suppl 6, p.vi99-vi105

2013

Volltextzugriff (PDF)

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2010-05, Vol.21 (suppl-5), p.v116-v119

2010

Volltextzugriff (PDF)

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort

Annals of oncology, 2016-02, Vol.27 (2), p.281-286

2016

Volltextzugriff (PDF)

1791P Thoracic radiotherapy plus maintenance durvalumab after first-line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ED-SCLC): A multicenter single-arm open-label phase II trial (SAKK 15/19)tle

Annals of oncology, 2024-09, Vol.35, p.S1065-S1065

2024

Volltextzugriff (PDF)

902 poster WHAT IS THE ADDITIONAL ROLE OF THE BREATH HOLD ACQUISITION USING F-18 FDG PET/CT IN STAGING NON-SMALL CELL LUNG CANCER (NSCLC) PRIOR TO STEREOTACTIC BODY RADIOTHERAPY (SBRT)?

Radiotherapy and oncology, 2011, Vol.99, p.S346-S347

2011

Volltextzugriff (PDF)

63PD LUNG CANCER IN WOMEN IN ST. GALLEN, EASTERN SWITZERLAND. AN ANALYSIS OF SEX-ASSOCIATED DIFFERENCES IN SMOKING HABITS, DISEASE PRESENTATION AND SURVIVAL

Lung cancer (Amsterdam, Netherlands), 2009, Vol.64, p.S32-S32

2009

Volltextzugriff (PDF)

Nanoshuttles propelled by motor proteins sequentially assemble molecular cargo in a microfluidic device

Lab on a chip, 2014-10, Vol.14 (19), p.3729-3738

2014

Volltextzugriff (PDF)

Covalent Cargo Loading to Molecular Shuttles via Copper-free “Click Chemistry”

Biomacromolecules, 2012-12, Vol.13 (12), p.3908-3911

2012

Volltextzugriff (PDF)

893 poster NON-GATED F-18 FDG PET/CT FOR TARGET VOLUME DELINEATION IN STEREOTACTIC BODY RADIATION THERAPY (SBRT) IN PATIENTS WITH STAGE I NON-SMALL CELL LUNG CANCER (NSCLC) OR HYPERMETABOLIC OLIGOMETASTATIC LUNG LESIONS

Radiotherapy and oncology, 2011, Vol.99, p.S343-S344

2011

Volltextzugriff (PDF)

970TiP SKYSCRAPER-05: Phase II study of neoadjuvant atezolizumab (Atezo) + tiragolumab (Tira) with or without platinum-based chemotherapy (CT) in patients (Pts) with locally advanced resectable stage II‒IIIB NSCLC

Annals of oncology, 2022-09, Vol.33, p.S990-S991

2022

Volltextzugriff (PDF)

2201P Malignant pleural mesothelioma (MPM)-specific DNA methylation patterns in patients using liquid biopsies

Annals of oncology, 2023-10, Vol.34, p.S1137-S1137

2023

Volltextzugriff (PDF)

1412P SAKK 17/18-ORIGIN trial: Efficacy and safety from a multicenter phase II trial of gemcitabine and atezolizumab in patients with advanced NSCLC progressing on immune checkpoint inhibitors

Annals of oncology, 2023-10, Vol.34, p.S807-S808

2023

Volltextzugriff (PDF)

2191P Real-world outcomes of patients with malignant pleural mesothelioma (MPM) treated with combination nivolumab and ipilimumab in the first- or later line setting

Annals of oncology, 2023-10, Vol.34, p.S1133-S1134

2023

Volltextzugriff (PDF)

How I Decide 1st Line Treatment Options for Metastatic NSCLC Without Driver Mutations - Balancing Efficacy, Toxicity and Cost: ES09.03

Journal of thoracic oncology, 2019-10, Vol.14 (10 Suppl), p.S36-S36

Frueh, M

2019

Volltextzugriff (PDF)

1 – 25 von 738

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(589)
Mit Volltextzugriff
(641)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)

ES09.03 How I Decide 1st Line Treatment Options for Metastatic NSCLC Without Driver Mutations - Balancing Efficacy, Toxicity and Cost

Prognostic impact of the use of antibiotics in patients with advanced non-small cell lung cancer (NSCLC) receiving PD-(L)1 targeting monoclonal antibodies

SAKK 17/16 - Lurbinectedin monotherapy in patients with progressive malignant pleural mesothelioma: A multicenter, single-arm phase II trial

Treatment (tx) characteristics of patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) receiving atezolizumab (atezo) monotherapy in US clinical practice

61PD 24h-blood profile gene expression biomarkers of the response to targeted therapy in advanced non-squamous non-small cell lung cancer (NSCLC)

IMpower150: Clinical safety, tolerability and immune-related adverse events in a phase III study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous NSCLC

A multiwavelength study of the M dwarf binary YY Geminorum

169P Chemotherapy is not superior to erlotinib in pretreated patients with advanced non-small cell lung cancer (NSCLC): A retrospective study

143PD Bevacizumab and pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous NSCLC: Results of the expanded SAKK19/09 trial

One-step, wash-free, bead-based immunoassay employing bound-free phase detection

Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort

1791P Thoracic radiotherapy plus maintenance durvalumab after first-line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ED-SCLC): A multicenter single-arm open-label phase II trial (SAKK 15/19)tle

902 poster WHAT IS THE ADDITIONAL ROLE OF THE BREATH HOLD ACQUISITION USING F-18 FDG PET/CT IN STAGING NON-SMALL CELL LUNG CANCER (NSCLC) PRIOR TO STEREOTACTIC BODY RADIOTHERAPY (SBRT)?

63PD LUNG CANCER IN WOMEN IN ST. GALLEN, EASTERN SWITZERLAND. AN ANALYSIS OF SEX-ASSOCIATED DIFFERENCES IN SMOKING HABITS, DISEASE PRESENTATION AND SURVIVAL

Nanoshuttles propelled by motor proteins sequentially assemble molecular cargo in a microfluidic device

Covalent Cargo Loading to Molecular Shuttles via Copper-free “Click Chemistry”

893 poster NON-GATED F-18 FDG PET/CT FOR TARGET VOLUME DELINEATION IN STEREOTACTIC BODY RADIATION THERAPY (SBRT) IN PATIENTS WITH STAGE I NON-SMALL CELL LUNG CANCER (NSCLC) OR HYPERMETABOLIC OLIGOMETASTATIC LUNG LESIONS

970TiP SKYSCRAPER-05: Phase II study of neoadjuvant atezolizumab (Atezo) + tiragolumab (Tira) with or without platinum-based chemotherapy (CT) in patients (Pts) with locally advanced resectable stage II‒IIIB NSCLC

2201P Malignant pleural mesothelioma (MPM)-specific DNA methylation patterns in patients using liquid biopsies

1412P SAKK 17/18-ORIGIN trial: Efficacy and safety from a multicenter phase II trial of gemcitabine and atezolizumab in patients with advanced NSCLC progressing on immune checkpoint inhibitors

2191P Real-world outcomes of patients with malignant pleural mesothelioma (MPM) treated with combination nivolumab and ipilimumab in the first- or later line setting

How I Decide 1st Line Treatment Options for Metastatic NSCLC Without Driver Mutations - Balancing Efficacy, Toxicity and Cost: ES09.03

Suchergebnisse filtern